Loading publications…
The last 5 uploaded publications
Real-world outcomes of immunosuppressed patients with Merkel cell carcinoma treated with immune checkpoint inhibitors.
William Mullally, Andrew S. Brohl, Aisha Ghaus, Mark Shackleton, Yang Wang, Shahneen Sandhu, Jürgen Becker, Marcin Dzienis, Liam Dwyer, Jenny Lee, Adnan Khattak, Lydia Warburton, Christopher Steer, Wen Xu (2025). Real-world outcomes of immunosuppressed patients with Merkel cell carcinoma treated with immune checkpoint inhibitors.. , 43(16_suppl), DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.9587.
Article62 days agoTwo-year efficacy and safety update from JAVELIN Merkel 200 part A: A registrational study of avelumab in metastatic merkel cell carcinoma (mMCC) progressed on chemotherapy
Tom van Hagen, Shahneen Sandhu, Paul Nghiem, Shailender Bhatia, Andrew S. Brohl, Omid Hamid, Janice M. Mehnert, Patrick Terheyden, Kent C. Shih, Isaac Brownell, Célèste Lebbé, Karl D. Lewis, Gerald P. Linette, Michèle Milella, Meliessa Hennessy, Marcis Bajars, Christine Hicking, Sandra P. D’Angelo (2018). Two-year efficacy and safety update from JAVELIN Merkel 200 part A: A registrational study of avelumab in metastatic merkel cell carcinoma (mMCC) progressed on chemotherapy. , 14
Article62 days agoTwo-year efficacy and safety update from JAVELIN Merkel 200 part A: A registrational study of avelumab in metastatic merkel cell carcinoma (mMCC) progressed on chemotherapy
Tom van Hagen, Shahneen Sandhu, Paul Nghiem, Shailender Bhatia, Andrew S. Brohl, Omid Hamid, Janice M. Mehnert, Patrick Terheyden, Kent C. Shih, Isaac Brownell, Célèste Lebbé, Karl D. Lewis, Gerald P. Linette, Michèle Milella, Meliessa Hennessy, Marcis Bajars, Christine Hicking, Sandra P. D’Angelo (2018). Two-year efficacy and safety update from JAVELIN Merkel 200 part A: A registrational study of avelumab in metastatic merkel cell carcinoma (mMCC) progressed on chemotherapy. , 14
Article62 days ago